Musculoskeletal Disorders Drugs Market By Product Type (Nonsteroidal Anti-Inflammatory Drugs, Conventional Disease-Modifying Antirheumatic Drugs, Biologic Disease-Modifying Antirheumatic Drugs, Targeted Synthetic Disease-Modifying Antirheumatic Drugs, Corticosteroids, Osteoporosis Drugs, Gout Drugs, Other Musculoskeletal Drugs); By Application (Osteoarthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Axial Spondyloarthritis, Osteoporosis, Gout, Other Musculoskeletal Disorders); By Route of Administration (Oral, Injectable, Topical); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies); By End User (Hospitals, Rheumatology Clinics, Orthopedic and Musculoskeletal Clinics, Primary Care Centers, Specialty Bone-Health and Osteoporosis Clinics, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Musculoskeletal Disorders Drugs Market: Payer Pressure, Biosimilar Density, and Protected Brands Redraw the Value Pool

The Global Musculoskeletal Disorders Drugs Market is projected to grow from USD 73.42 billion in 2025 to USD 111.11 billion by 2032, expanding at a 6.1% CAGR during the forecast period, according to Strategic Market Research.

 

The Musculoskeletal Disorders Drugs Market is not expanding as one uniform pharmaceutical category. Osteoarthritis produces the largest treatment volume, but much of that demand is generic, intermittent, or purchased outside prescription channels. Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, osteoporosis, and uncontrolled gout create smaller but more commercially concentrated pathways because treatment can be long term, specialist directed, reimbursed, and tied to switching or repeat administration. The market is therefore better assessed through treated patients, treatment persistence, benefit design, biosimilar conversion, and product-level revenue movement than through the approximately 1.71 billion-person global musculoskeletal burden alone.

 

Disease Scale Creates Demand, but Treatment Intensity Determines Value

The patient ceiling remains substantial. A Global Burden of Disease-based analysis estimated 606.9 million people living with osteoarthritis in 2021, while a separate 2025 analysis placed the rheumatoid arthritis population at 17.92 million in the same year. Gout affected an estimated 55.8 million people globally in 2020 and is projected to reach 95.8 million by 2050. These populations do not carry equal pharmaceutical value. Osteoarthritis can generate high unit use but weak pricing. Rheumatoid arthritis supports recurring DMARD, biologic, and targeted-therapy demand. Gout combines low-cost acute and preventive medicines with a narrow, high-value refractory segment.

The United States shows the same separation between diagnosed burden and pharmaceutical value. CDC reported diagnosed arthritis in 21.3% of adults in 2024 and recorded 9.9 million office-based physician visits with osteoarthritis as the primary diagnosis. These figures support a large treatment environment, but they do not identify active prescription use, severity, or suitability for advanced therapy. Applying one drug-spend assumption across all arthritis patients would overstate branded opportunity and understate the importance of indication, treatment line, and payer channel.

 

Inflammatory Arthritis Keeps the Strongest Recurring Economics

Inflammatory arthritis carries the most predictable specialty-drug structure because treatment is intended to control disease over years rather than respond to isolated pain episodes. NICE continues to recommend starting a conventional DMARD as soon as possible in active rheumatoid arthritis, ideally within three months of persistent symptoms. Failure to achieve remission or low disease activity opens the pathway to additional conventional drugs, biologics, and targeted synthetic therapies. Each escalation becomes a commercial event involving specialist referral, prior authorization, specialty-pharmacy onboarding, repeat monitoring, or switching.

Competition is moving beyond broad “biologic versus conventional drug” positioning. New products increasingly need stronger response depth, convenient administration, acceptable safety, or control across multiple disease domains. Bimekizumab received U.S. approvals in September 2024 for psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. In March 2026, UCB reported statistical superiority over risankizumab on the ACR50 endpoint at Week 16 in the 553-patient BE BOLD psoriatic arthritis study. Head-to-head evidence is commercially important because it gives payers and specialists a clearer basis for sequencing two protected biologic classes.

UCB reported that more than 116,000 patients had accessed Bimzelx across all approved indications by the end of 2025. That figure cannot be assigned entirely to musculoskeletal disease because the product also serves dermatology indications. It nevertheless shows how a multi-indication immunology launch can scale through shared specialist education, payer contracting, manufacturing, and patient-support infrastructure. The commercial advantage comes from reusing one platform across related inflammatory diseases rather than depending on a single patient pool.

 

Biosimilar Density Converts Brand Franchises Into Procurement Battles

The FDA biosimilar list shows how quickly competition is widening. Avtozma, a tocilizumab biosimilar relevant to rheumatoid arthritis, was approved in January 2025. Adalimumab, infliximab, etanercept, ustekinumab, rituximab, and tocilizumab now face follow-on competition in the United States. Clinical similarity is only the entry requirement. Commercial performance depends on formulary status, interchangeability, acquisition cost, rebate strategy, provider confidence, supply continuity, and whether the medicine moves through the pharmacy or medical benefit.

AbbVie’s portfolio illustrates the resulting value migration. First-quarter 2026 global Humira revenue fell 38.6% year over year to USD 688 million, while Rinvoq increased 23.3% to USD 2.119 billion. Both totals contain non-musculoskeletal indications, but the direction remains commercially relevant: value lost from a biosimilar-exposed TNF franchise is being recaptured through a newer protected mechanism. Companies with ageing biologics need successor brands capable of retaining switch patients before procurement pressure turns class growth into net revenue decline.

Amgen reported a similarly sharp payer and lifecycle effect. First-quarter 2026 Enbrel sales declined 37% to USD 320 million, while AMJEVITA and AMGEVITA sales increased 27% to USD 173 million. The contrast captures the new economics of established biologic classes: originator erosion and biosimilar growth can occur inside the same corporate portfolio, yet lower-priced follow-on volume may not replace the margin lost from the reference product.

 

Bone Health Splits Between Untreated Risk and Denosumab Erosion

Osteoporosis presents one of the clearest cases of untreated demand colliding with rapid price competition. The latest standardized U.S. DXA benchmark identified osteoporosis in 12.6% of adults aged 50 and older and low bone mass in 43.1% during 2017–2018. Europe’s most comparable regional assessment estimated that 14.8 million treatment-eligible women remained untreated in 2019, equal to a 71% treatment gap. These datasets remain useful as funnel indicators, but they are not current treated-patient counts and should not be converted directly into pharmaceutical revenue.

The competitive environment is much newer. The FDA approved Jubbonti as the first interchangeable biosimilar to Prolia in March 2024, and Sandoz launched it in the United States in June 2025. Counting the Prolia-referencing entries on the FDA’s July 1, 2026 biosimilar list shows ten denosumab biosimilar brands approved between March 2024 and March 2026. The category moved from first-entry competition to dense multi-supplier availability in roughly two years, giving procurement teams several alternatives for a repeat six-month injection pathway that was previously concentrated around one reference product.

The revenue effect is already visible. Amgen reported first-quarter 2026 Prolia sales of USD 727 million, down 34% year over year because of lower volume, lower net selling price, and expanding biosimilar competition. EVENITY moved in the opposite direction, rising 27% to USD 562 million. UCB separately reported that Evenity had reached more than 1.3 million women globally since launch by the end of 2025. Bone-health value is shifting from a mature antiresorptive biologic toward biosimilar supply and protected bone-building therapy for higher-risk patients.

Access expansion still matters, but it will not automatically restore originator value. NICE recommended abaloparatide in August 2024 for postmenopausal women at very high fracture risk when standard options are unsuitable and estimated that more than 14,000 women in England could benefit. This creates a defined new treatment pool, but entry remains controlled through risk-based eligibility and cost-effectiveness. Osteoporosis growth will depend on identifying high-risk patients and maintaining sequential therapy, not simply on counting people with low bone density.

 

Osteoarthritis Supports Volume, Not a Single Premium Market

Osteoarthritis remains the largest disease pool, but it is the weakest segment for uniform branded pricing. NICE recommends topical NSAIDs for knee osteoarthritis and advises using medicines at the lowest effective dose for the shortest possible period. Pharmacological care is used alongside exercise, weight management, and other non-drug measures, while some advanced patients eventually move toward surgery. Prescription datasets also miss part of the market because common pain medicines may be purchased over the counter.

Commercial opportunity is concentrated in differentiated delivery, improved tolerability, safer use in older patients with multiple conditions, and therapies capable of demonstrating more than temporary pain relief. Large prevalence figures may support volume assumptions for topical and oral medicines, but they do not justify premium revenue assumptions. Generic competition, episodic use, safety limits, OTC leakage, and eventual procedure substitution keep the segment broad but fragmented.

 

Refractory Gout Defends Specialist Pricing

Most gout treatment is delivered through inexpensive flare medicines and long-term urate-lowering drugs. Premium value sits in the smaller group with uncontrolled or refractory disease, prior-treatment failure, high crystal burden, and specialist access. That funnel is narrow, but each treated patient can generate meaningful infusion, monitoring, and support-service value.

Amgen’s KRYSTEXXA performance confirms this model. Sales increased 13% for full-year 2025 and rose another 8% year over year to USD 255 million in the first quarter of 2026. The company attributed the quarterly increase primarily to higher net selling price rather than broad volume expansion. Severe gout therefore behaves more like a specialist rare-disease market than a conventional primary-care arthritis category. Commercial success depends on patient identification, prior authorization, infusion capacity, and maintaining differentiation in a small eligible population.

 

Medicare Negotiation Has Become a Reported Revenue Driver

Medicare price negotiation has moved from policy risk to a product-level revenue event. In 2023, 48,000 Medicare Part D enrollees used Enbrel, generating approximately USD 2.952 billion in gross covered prescription-drug costs. Its negotiated 30-day price became USD 2,355 in 2026, 67% below the 2023 list price of USD 7,106. The comparison is against list price rather than the previous confidential net price, but Amgen’s 2026 results confirm that lower net selling prices are affecting the franchise.

Administration channel also changes market economics. CMS generally reimburses separately payable Part B drugs at average sales price plus 6%, supporting physician-office and hospital-outpatient pathways for infused or injected medicines. Self-administered products are more dependent on Part D or commercial pharmacy benefits. Manufacturers therefore manage two commercial systems: specialty-pharmacy access and medical-benefit reimbursement. Route of administration influences buyer incentives, patient cost sharing, inventory risk, and the speed of biosimilar conversion.

 

Europe Expands Access Under Tight Cost Filters

European demand is supported by substantial osteoporosis under-treatment and established inflammatory-arthritis pathways, but access is filtered through health technology assessment, national reimbursement, tenders, and cost-sensitive prescribing. NICE’s rheumatoid arthritis pathway links advanced treatment to prior response and eligibility, while its abaloparatide decision opened access only within a very-high-fracture-risk population. Europe can expand treated volume without producing equal growth in value per prescription or administration.

This structure favors biosimilars, products with convincing comparative evidence, and suppliers that can support national or regional procurement. It weakens brands that rely on list-price preservation without a measurable clinical, safety, or administration advantage. Patient growth and revenue growth must therefore be tracked separately across European markets.

 

Portfolio Winners and Erosion Risks

Amgen, AbbVie, UCB, Sandoz, Celltrion, Teva, Alvotech, Pfizer, Johnson & Johnson, Novartis, Eli Lilly, and other manufacturers compete across different disease and reimbursement pools. No company controls the full market. Amgen’s 2026 results show Prolia and Enbrel erosion alongside Evenity and KRYSTEXXA growth. AbbVie is replacing Humira decline with Rinvoq expansion. UCB is building Bimzelx through additional rheumatology indications and head-to-head evidence. Sandoz and other biosimilar suppliers are targeting established denosumab and immunology volumes.

The strongest competitive positions combine a protected product, clear treatment-line relevance, payer evidence, convenient administration, and infrastructure that supports persistence. The weakest positions sit in mature classes where medicines are increasingly substitutable and purchasing influence has shifted from individual prescribers toward formularies, benefit managers, tender authorities, and integrated health systems.

 

Strategic Interpretation

The Musculoskeletal Disorders Drugs Market is growing through value redistribution rather than uniform price and volume expansion. Inflammatory arthritis remains the main specialty-drug engine, but newer brands must earn share through comparative efficacy and treatment sequencing. Osteoporosis contains substantial untreated need, yet denosumab biosimilars are compressing the value of the established treated pool faster than health systems are closing the diagnosis and treatment gap. Osteoarthritis provides the largest volume ceiling but limited premium economics. Severe gout demonstrates that a small, tightly defined population can support strong revenue when treatment is differentiated and reimbursement is maintained.

 

Musculoskeletal Disorders Drugs Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 73.42 Billion
Revenue Forecast in 2032	USD 111.11 Billion
Overall Growth Rate	CAGR of 6.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By Route of Administration, By Distribution Channel, By End User, By Geography
By Product Type	Nonsteroidal Anti-Inflammatory Drugs, Conventional Disease-Modifying Antirheumatic Drugs, Biologic Disease-Modifying Antirheumatic Drugs, Targeted Synthetic Disease-Modifying Antirheumatic Drugs, Corticosteroids, Osteoporosis Drugs, Gout Drugs, Other Musculoskeletal Drugs
By Application	Osteoarthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Axial Spondyloarthritis, Osteoporosis, Gout, Other Musculoskeletal Disorders
By Route of Administration	Oral, Injectable, Topical
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies
By End User	Hospitals, Rheumatology Clinics, Orthopedic and Musculoskeletal Clinics, Primary Care Centers, Specialty Bone-Health and Osteoporosis Clinics, Homecare Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	• Rising prevalence of osteoarthritis, rheumatoid arthritis, osteoporosis, and chronic musculoskeletal conditions • Increasing adoption of biologic and targeted therapies for inflammatory disorders • Growing demand for personalized treatment approaches and advanced disease management solutions
Customization Option	Available upon request